ClinicalTrials.gg
CompletedNCT01530542Updated Feb 24, 2012

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

A Phase 1 interventional study of oxycodone hydrochloride and oxycodone hydrochloride in Analgesia, Acute Pain and Chronic Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
235th of 320
35 · median 84
Started
2010
with 4 others
Phase 1
27 of 351
3 open now
Registered
38th of 351
by date

Among the 351 studies in Acute Pain with a site in United States, this one is the 235th largest by enrollment of the 320 interventional ones that give a count, is one of 5 that started in 2010, is one of 27 in phase 1, and was the 38th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 5-dosing period study to characterize the pharmacokinetics (process by which oxycodone is absorbed, distributed, metabolized, and eliminated by the body) and the effects of food on the pharmacokinetics of oxycodone. The study will take place over approximately two and a half months and will consist of three phases: a screening visit to determine eligibility for the study, a 5-dosing period treatment phase, and an end-of-study visit.

03

Conditions studied

  • Analgesia
  • Acute Pain
  • Chronic Pain
  • Narcotic Abuse
  • Opioid-related Disorders

Keywords

  • bioavailability
  • food effect
  • oxycodone
  • management of acute and chronic moderate to severe pain
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects between 18 and 55 years of age (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of disease;
  • History of obstructive sleep apnea;
  • Positive urine drug test.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: oxycodone hydrochloride

  • Experimental
    Treatment B

    Drug: oxycodone hydrochloride

  • Experimental
    Treatment C

    Drug: oxycodone hydrochloride

  • Experimental
    Treatment D

    Drug: oxycodone hydrochloride

  • Experimental
    Treatment E

    Drug: marketed oxycodone hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, and 24 hours post-dose.

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, and 24 hours post-dose.

  3. Area under the Concentration-Time Curve (AUC)

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, and 24 hours post-dose.

  4. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, and 24 hours post-dose.

  5. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, and 24 hours post-dose.

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Screening up to approximately 3 months

  2. Percentage of participants with treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    Time frame: Screening up to approximately 3 months

  3. Change from Baseline in Diastolic Blood Pressure at each Post-Dose Assessment

    Time frame: 0, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose.

  4. Change from Baseline in Systolic Blood Pressure at each Post-Dose Assessment

    Time frame: 0, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose.

  5. Change from Baseline to each Post-Dose Assessment in Heart Rate

    Time frame: 0, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose.

  6. Change from Baseline to each Post-Dose Assessment in Respiratory Rate

    Time frame: 0, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose.

  7. Change from Baseline to each Post-Dose Assessment in Pulse Oximetry (SpO2, %)

    Time frame: 0, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose.

  8. Change from Screening to End-of-Study Assessment in Hematology Parameters

    Time frame: Screening up to approximately 3 months

  9. Change from Screening to End-of-Study Assessment in Chemistry Parameters

    Time frame: Screening up to approximately 3 months

  10. Change from Screening to End-of-Study Assessment in Urinalysis Parameters

    Time frame: Screening up to approximately 3 months

  11. Change from Screening to End-of-Study Assessment in ECG Measurements

    Time frame: Screening up to approximately 3 months

07

Study locations

1 site
  • Pfizer Investigational Site
    San Antonio, Texas 78217, United States
08

References and documents

Publications

  • Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, Rolleri R. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. Clin Ther. 2012 Jul;34(7):1601-12. doi: 10.1016/j.clinthera.2012.05.009. Epub 2012 Jun 19. PubMed 22717418 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2012
First posted
Feb 10, 2012
Start
Jul 2010
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Last update
Feb 24, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01530542
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 10, 2012
Start date
Jul 2010
Primary completion
Sep 2010
Completion
Sep 2010
Last update
Feb 24, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion